What caused the sharp drop in PHASQ stock today?

PHASQ stock fell due to thin liquidity, continued Chapter 11 restructuring uncertainty, low average volume, and ongoing pipeline risk for bentracimab (PB2452), which together amplified negative price action.

Does PHASQ stock have any realistic price targets?

Price scenarios range from a conservative **$0.000100** to a base **$0.00100** and optimistic **$0.01000**, driven by financing and trial success; these are scenario estimates, not guarantees.

How does Meyka AI grade PHASQ stock affect the outlook?

Meyka AI gives PHASQ a **59.07 (C+) HOLD** grade based on benchmark and sector comparisons, financial metrics, and analyst inputs; the grade is informational and not investment advice.

What are the main risks if I consider PHASQ stock?

Main risks include Chapter 11 outcomes, dilution from capital raises, clinical trial failure for PB2452, and extremely low liquidity that can magnify losses and widen spreads.

US Stocks

$0.000001 PHASQ stock on PNK 13 Jan 2026: PhaseBio Pharmaceuticals outlook

ByHuzaifa Zahoor January 13, 2026January 13, 2026

PHASQ stock opened market hours on 13 Jan 2026 at $0.000001, down -99.00% from the previous close of $0.000100 on the PNK exchange in the United States. Trading volume was 2,500.00 shares versus a 50‑day average of 22,310.00, positioning PhaseBio Pharmaceuticals among today’s top losers. The move reflects lingering Chapter 11 restructuring risk, pipeline uncertainty around bentracimab (PB2452), and thin liquidity. We examine valuation, key ratios, Meyka AI grading, and price scenarios to help investors understand the downside exposure and any potential catalysts.